Galectin Therapeutics Inc.
GALTHealthcare|Biotechnology|US
$3.14
+0.15 (+5.19%)
Cash / Share
$0.20
Clinical Trials (12)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04365868 Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis | Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis | P2P3 | Terminated | 357 | RCT, Double-blind | belapectin, Placebo |
| NCT02462967 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis | Hypertension, Portal | P2 | Completed | 162 | RCT, Double-blind | GR-MD-02, Placebo |
| NCT00110721 GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer | Colorectal Cancer | P2 | Terminated | 20 | Open-label | GM-CT-01 plus 5-Fluorouracil |
| NCT02407041 An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis | Psoriasis | P2 | Completed | 5 | Open-label | GR-MD-02 |
| NCT00386516 Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer | Cancer of the Bile Duct, Gallbladder Cancer | P2 | Withdrawn | — | Open-label | GM-CT-01, 5-Fluorouracil |
| NCT00388700 A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer | Colorectal Cancer | P2 | Withdrawn | — | Open-label | GM-CT-01, 5-Fluorouracil, Leukovorin, bevacizumab |
| NCT02421094 Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis | Nonalcoholic Steatohepatitis | P2 | Completed | 30 | RCT, Double-blind | GR-MD-02, Placebo |
| NCT00054977 Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors | Colorectal Cancer, Lung Cancer | P1 | Completed | 40 | Open-label | GM-CT-01, 5-fluorouracil |
| NCT02117362 Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma | Metastatic Melanoma | P1 | Completed | 8 | Open-label | 1 mg/kg GR-MD-02, 2 mg/kg GR-MD-02, 4 mg/kg GR-MD-02, 8 mg/kg GR-MD-02, Ipilimumab |
| NCT02575404 GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients | Melanoma, Non-Small Cell Lung Cancer | P1 | Completed | 36 | Open-label | GR-MD-02, Pembrolizumab |
| NCT04332432 GT-032 Belapectin Hepatic Impairment | Hepatic Impairment | P1 | Completed | 38 | Open-label | belapectin |
| NCT01899859 Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis | Non-Alcoholic Steatohepatitis (NASH) | P1 | Completed | 31 | RCT, Double-blind | GR-MD-02, Placebo |